VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO Italy 2020 | Assessment of MRD in AML

Francesco Buccisano, MD, University Tor Vergata, Rome, Italy, outlines the use of minimal residual disease (MRD) measurement in acute myeloid leukemia and outlines the use of MRD negativity in complete remission. Dr Buccisano also discusses assays to measure MRD, including next-generation sequencing and flow cytometry as well as the importance of improving the sensitivity of MRD assays. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter